Author:
Zhou Lei,Wu Jianqiang,Wei Zairong,Zheng Yuehong
Abstract
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, having become a global public health problem, so the pathophysiological mechanisms and therapeutic strategies of CVDs need further study. Legumain is a powerful enzyme that is widely distributed in mammals and plays an important role in a variety of biological processes. Recent research suggests that legumain is associated with the occurrence and progression of CVDs. In this review, we provide a comprehensive overview of legumain in the pathogenesis of CVDs. The role of legumain in CVDs, such as carotid atherosclerosis, pulmonary hypertension, coronary artery disease, peripheral arterial disease, aortic aneurysms and dissection, is discussed. The potential applications of legumain as a biomarker of these diseases are also explored. By understanding the role of legumain in the pathogenesis of CVDs, we aim to support new therapeutic strategies to prevent or treat these diseases.
Reference74 articles.
1. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study;Dagenais;The Lancet,2020
2. Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials;Liu;Nat Rev Cardiol,2018
3. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase;Chen;J Biol Chem,1997
4. The two cysteine endopeptidases of legume seeds: purification and characterization by use of specific fluorometric assays;Kembhavi;Arch Biochem Biophys,1993
5. Legumain promotes atherosclerotic vascular remodeling;Ozawa;Int J Mol Sci,2019